Robbie Rogart Jost
Overview
With over a decade of experience managing complex consumer litigation, Robbie Rogart Jost knows that success requires a multi-faceted approach—understanding the product, as well as the client’s goals, business model, industry, and the regulatory framework in which it operates.
Career & Education
- University of Virginia, B.A., high honors, political philosophy, policy & law, 2009
- University of Virginia School of Law, J.D., 2012
- District of Columbia
- Virginia
Robbie's Insights
Client Alert | 3 min read | 10.29.24
The Ink is Dry: FDA Issues Final Guidance for Tattoo Industry
On October 25, 2024, FDA issued final guidance to the tattoo industry on the preparation, packing and holding of tattoo inks aimed at preventing the risk of microbial contamination. FDA is getting involved because tattoo ink is considered a cosmetic product regulated by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
Press Coverage | 10.08.24
Client Alert | 1 min read | 08.06.24
Cosmetics Direct Gets Two Portal “Fillers” – Discontinuation and Relisting Features Added
Client Alert | 2 min read | 06.26.24
Representative Matters
Class and Mass Action Litigation
- Defending a global health care services company as national counsel for its entire docket of medical device and pharmaceutical product liability litigation.
- Defending an international medical device manufacturer as national counsel in product liability litigation in the United States, including issues related to the Federal Food, Drug and Cosmetic Act and the Premarket Approval (PMA) process. In over a decade in this role, the company has never paid a judgment.
- Defending a home appliance manufacturer in putative class action consumer protection litigation concerning alleged impacts to human health from gas cooking emissions.
- Defended a large medical device manufacturer in the U.S. as national counsel in mass tort litigation involving product liability lawsuits in numerous state, federal, and international courts.
- Defended a pharmaceutical distributer for a Fortune 20 company in a pharmaceutical MDL involving class and mass actions.
- Defended universities in class action litigation alleging breaches of contract and unjust enrichment arising from closures during the COVID-19 pandemic.
- Defended Blue Cross and Blue Shield companies in MDL involving national and statewide class actions asserting antitrust claims.
- Defended a product manufacturer in MDL national class actions asserting claims under the Telephone Consumer Protection Act (TCPA).
- Negotiated and supported “limited fund” settlement of hundreds of class action lawsuits against a university following its loss of accreditation.
Personal Injury Litigation
- Defending manufacturer of cold and hot packs in numerous actions in various state and federal courts alleging burns and other injuries in connection with use of those packs.
- Defending manufacturer of a syringe in international products liability litigation related to alleged eye injuries in connection with use of the syringe.
- Defending distributer of mobility devices (rollators, walkers, knee scooters) in various state and federal court product liability actions related to alleged injuries in connection with use of those devices.
- Defended a pharmacy in state court litigation alleging brain injury in connection with alleged failure to provide appropriate nutritional monitoring and support.
Risk Management Counseling
-
- Assessing legal risks in connection with new business proposition for hazmat emergency response call center, including development of associated risk mitigation strategies and drafting of contractual documents.
- Assessing legal risks for trade association and its membership of development of process safety tool, including development of associated risk mitigation strategies.
Robbie's Insights
Client Alert | 3 min read | 10.29.24
The Ink is Dry: FDA Issues Final Guidance for Tattoo Industry
On October 25, 2024, FDA issued final guidance to the tattoo industry on the preparation, packing and holding of tattoo inks aimed at preventing the risk of microbial contamination. FDA is getting involved because tattoo ink is considered a cosmetic product regulated by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
Press Coverage | 10.08.24
Client Alert | 1 min read | 08.06.24
Cosmetics Direct Gets Two Portal “Fillers” – Discontinuation and Relisting Features Added
Client Alert | 2 min read | 06.26.24
Insights
FDA Issues First-of-Its-Kind Guidance for Manufacturers of 3D-Printed Medical Devices
|12.20.17
Crowell & Moring's Recent Happenings in Advertising & Product Risk Management – December 2017
Let’s Talk All Things MoCRA – Is Your Company Prepared?
|06.11.24
Crowell & Moring And Thomson Reuters Team Up To Develop Westlaw Edge Quick Check's Future
|08.15.19
Thomson Reuters Legal Current
MedTech Article Discusses FDA Authority Over Bassinet
|06.01.23
Crowell & Moring’s Retail & Consumer Products Law Observer
- |
03.23.17
Crowell & Moring's Retail & Consumer Products Law Observer
Update: Class Action Reform Bill Passes House 220-201
|03.17.17
Crowell & Moring's Retail & Consumer Products Law Observer
Robbie's Insights
Client Alert | 3 min read | 10.29.24
The Ink is Dry: FDA Issues Final Guidance for Tattoo Industry
On October 25, 2024, FDA issued final guidance to the tattoo industry on the preparation, packing and holding of tattoo inks aimed at preventing the risk of microbial contamination. FDA is getting involved because tattoo ink is considered a cosmetic product regulated by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
Press Coverage | 10.08.24
Client Alert | 1 min read | 08.06.24
Cosmetics Direct Gets Two Portal “Fillers” – Discontinuation and Relisting Features Added
Client Alert | 2 min read | 06.26.24